Mosvold Hospital is a government district hospital situated in northern KwaZulu-Natal, a province with an antenatal HIV prevalence of 39%. A previous study indicated that 45% of deaths certified at Mosvold Hospital were due to HIV/AIDS. The antiretroviral roll-out programme commenced at Mosvold Hospital on 16 September 2004.
Introduction
Mosvold Hospital is situated in northern KwaZulu-Natal near the borders of Swaziland and Mozambique. According to estimates by the Department of Health, the hospital serves a population of about 108 000. 1 The population is rural and poor, with adult unemployment at 60%. Five per cent of households have piped water and 3.6% of households are supplied with electricity. Government healthcare in the Ingwavuma sub-district, in which Mosvold Hospital is situated, is provided by the hospital, 10 residential clinics and three mobile clinic teams.
Entering of death statistics from Mosvold Hospital into a database was begun by the author in 2003 in order to be able to provide the information frequently requested from various sections of the Department of Health regarding patterns of mortality. It was also considered that such statistics would be useful for indicating the effectiveness of health services and priority areas for attention. It became immediately apparent that HIV/AIDS was the disease responsible for most mortality and primarily responsible for a low life expectancy.
In a previous study by the author, an analysis of eight months of mortality data from January to August 2003 indicated that HIV/AIDS was responsible for 45% of deaths and appeared to cause deaths in women at a younger age than in men. 2 On 16 September 2004, antiretroviral drugs (ARVs) were first prescribed to sufferers of AIDS at Mosvold Hospital as part of the National Antiretroviral Roll-out Programme. By 31 December 2005, 638 patients (399 females; 239 males) had been started on ARVs at Mosvold Hospital and attached clinics. By 31 December 2006, a total of 1 507 patients had started ARVs, of which 910 were females and 597 were males. This analysis was undertaken to investigate the continuing impact of HIV/AIDS on mortality and life expectancy and to see whether any effect of the antiretroviral roll-out programme could be observed 28 months into the programme.
The use of nevirapine for the prevention of maternal to child transmission was commenced in 2002, prior to the start of the study.
In a report, 'The impact of HIV/AIDS on adult mortality in South Africa', the authors estimate that 40% of the deaths of adults aged 15 to 49 years, and 20% of all adult deaths in South Africa in the year 2000 were due to HIV/AIDS. 3 This estimate was based on the dramatic increase in female deaths in the 25 to 29 years age group compared to 1985, and a less marked increase in male deaths in the 30 to 39 age group. The peak for female deaths was found to be between 25 and 29 years, and the peak for male deaths to be between 30 and 35. The authors noted that the details completed on death certificates tended to concentrate on opportunistic infections, rather than on the underlying HIV/AIDS. In another report, 'Causes of death in South Africa 1997-2001', the proportion of deaths due to HIV amongst females aged 15 to 29 was estimated to be 22.5%, compared to 8.5% for males of that age group. 4 The National HIV and Syphilis SeroPrevalence Survey of women attending public antenatal clinics in South Africa in 2005 estimated that KwaZulu-Natal was the province with the highest provincial sero-prevalence of HIV amongst antenatal attendees at public antenatal clinics, with 39.1% of antenatal clinic attendees being HIV positive, compared to an overall national HIV prevalence of 30.2%. 5 With a higher antenatal HIV prevalence than the national average, it is probable that the province will also have a higher proportion of deaths from HIV/AIDS compared to the rest of South Africa.
Methods
Data from the death certificates were captured mainly by the author, who is medically qualified. For five months of data capturing, from April to August 2005, the author was assisted by a data capturer, whose entries were checked by the author. Where a clear euphemism for HIV/AIDS or an AIDS-defining illness had been given, the author entered the underlying diagnosis as HIV/AIDS (see Table I ). 
Diagnosis Total

Acquired immunodeficiency 86
Immunocompromised 61
HIV entered under 'Other significant diagnosis' 55
Retroviral disease 39
Kaposi's sarcoma 9
Pneumocystis carinii pneumonia 6
Cryptococcal meningitis 6
Immunosuppressed 2
Immune deficiency 2
Acquired immunosuppression 2
Immunosuppression 1
Cerebral toxoplasmosis 1
Total of presumed HIV/AIDS diagnoses 270
Total deaths entered as HIV/AIDS 3956
Percentage of HIV/AIDS presumed from other diagnoses 6.8%
The items mainly followed those on the death notification form. The underlying diagnosis was captured in the same field as an only diagnosis. Certain euphemisms and AIDS-defining illnesses for HIV/AIDS (see Table I ) were captured as HIV/AIDS. In the case of an underlying diagnosis being interpreted by the author as HIV/AIDS, the underlying diagnosis was entered as HIV/AIDS and the original diagnosis was recorded under 'Diagnosis presumed HIV/AIDS' (see Table I ). After the commencement of data collection, medical officers were encouraged to be as clear and truthful as possible in their death notification entries.
The categories of diagnoses available in the database's drop-down list of diagnoses consisted of the notifiable medical conditions with HIV/AIDS. 7 Other diagnoses were added to the list as they were encountered.
Ethical considerations
The publication of statistics on the causes of death certified at Mosvold Hospital was approved by the Mosvold Hospital Ethical Committee on 11 September 2003.
Results
Of all the deaths entered as due to HIV/AIDS, 6.8% were inferred from the diagnoses given in Table I . Table II shows There is a peak of deaths in the 20 to 49 year age groups. There are also peaks in the zero to four year age group and between 70 and 84 years. The peak of deaths between the ages of 20 and 49 years appears to occur earlier among women than among men. The peak oc- Total Males 2003 22  1  5  4  2  28  70  48  49  44  28  11  19  14  25  21  11  10  0  1   Total Males 2004 39  6  4  5  11  26  51  58  53  38  23  20  14  16  13  13  5  4  4  2   Total Males 2005 74  9  2  6  7  38  48  62  53  53  17  26  18  15  12  16  7  12  1  1   Total Males 2006 68  3  2  6  16  33  54  55  52  41  27  24  12  20  13  12  8 Female total deaths 2003 15  6  2  6  35  55  85  44  36  24  21  14  21  23  36  38  26  14  5  2   Female total deaths 2004 39  5  1  9  29  68  64  71  34  35  29  13  15  16  25  22  11  16  5  1   Female total deaths 2005 78  8  10  8  45  71  75  68  43  40  24  23  22  22  17  23  15  15  5  2   Female total deaths 2006 36  4  8  9  37  48  70  51  34  30  26  12  19  23  22  48  20  13  6 Table II ) and there is no increase in average age at death from HIV/AIDS (see Table IV ).
Cause of death
It should be noted that the data is from early in the ARV programme. Most of the patients started on ARVs would have lived a year or more even without ARVs, and the numbers of patients taking ARVs increased steadily throughout 2005 and 2006. As more patients enter the programme, and more patients have taken ARVs for longer, it is still possible that the effect of the programme on life expectancy will become more demonstrable.
This study shows that HIV/AIDS remains the dominant public health concern in the sub-district, being responsible for most deaths and leading to a low average life expectancy of about 40 years.
It is important to continue to monitor trends in mortality to assess the continuing impact of HIV/AIDS and the efficacy of public health measures to counter the disease.
